If we accept Francke's definition of a clinical pharmacist, there's no question that we're talking about a specialist. And it's difficult to picture this seven-year graduate practicing anywhere but in a structured system such as a hospital or health center where he'll have access to the patient's medical history and records, and be in direct contact on a day-to-day basis with other health professionals. Thus, if clinical pharmacy is now or is going to be a specialty, pharmacy had better stop kidding itself that it can be practiced anywhere. Further, if we accept the specialty concept rather than the concept of overall direction, and if we buy the description of the clinical pharmacist as an "applied pharmacology generalist," we have what to me appears to be an incongruous situation-a pharmacy specialist-pharmacology generalist. Perhaps this reinforces the need to consider combining the two disciplines under one label. ...
Scientific Foundation For Clinical Pharmacy
Another point we must recognize is that the vast majority of self-proclaimed clinical pharmacists are in reality "generalists" operating without the benefit of a well-defined body of scientific knowledge or techniques distinctly recognized as belonging to "clinical pharmacy." I believe we need to build a sound scientific foundation for clinical pharmacy if we expect it to emerge into a distinct specialty of practice. Taking a thorough drug history, developing and monitoring a patient drug profile, providing drug information, instructing patients on proper use of medications, and monitoring adverse drug reactions and drug utilization EDITORIALS are certainly important aspects of the clinical concept, but they are not enough. Applying the elements of pharmacology, toxicology, biopharmaceutics and pharmacokinetics to clinical pharmacy will be necessary to impart true substance to its practice. A very few practitioners in a very few hospitals are practicing in this kind of depth.
The rigorous preparation required for a more sophisticated clinical pharmacy practice raises another problem, one that the profession has almost totally ignored up to this time. It has been said that the quality control in an educational system is who gets in. Although the caliber of pharmacy student seems to have improved in recent years and we have generated many bright, young practitioners, it is my impression that at least some schools are admitting, carrying and graduating students who really can't cut the mustard. More stringent entrance requirements and less reluctance on the part of schools to drop students are in order.
DO BASIC SCIENTISTS FIDDLE

WHILE THE CLINICAL FACULTY BURNS?
Harvey A.K. Whitney, Jr.
IN DISCUSSING THE PACE OF THE DEVELOPMENT of new directions for pharmacy, Francke said: "Rome was not built in a day. History has demonstrated that great social changes ... when they occur in a profession do not alter the attitudes and values of its members until a significant number of them assume new roles and perform successfully in them for two or three generations." I However, the pace of change is immeasurably faster now and pharmacists share an obligation to bring about a rapid metamorphosis in pharmacy .... it is my contention that examiners of health care in this country have not seriously considered the potential of pharmacists. Moreover, many of the basic scientists who lead Reprinted. in part. from Drug In/ell Clin Pharm 1971;5:73.
the faculties in our schools of pharmacy do not have an appreciation of the consequences of the changing health scene primarily because they are scientists and not practitioners ....
Many physicians, unlike pharmacists, have been quick to recognize that one step to easing the medical manpower shortage is through the utilization of paramedical personnel. This means making use of those health professionals presently available and creating new health assistants to fill any gaps. It has been said that the pharmacist "may sell a health-related product-but he is not accepted as a member of a health profession."> If one accepts this tenet, then the question becomes: "Do pharmacists want to become a member of the health team by contributing directly to patient care?" If they do, then we must also ask: "Where is the leadership in our schools of pharmacy required to forge ahead in the area of clinical pharmacy practice in both hospitals and in the community?"
The basic scientists who make up the majority of our pharmacy faculties and have been responsible for the curricula have done an excellent job of preparing students to be research scientists. Of course, the majority of students could not live up to the high standards for a doctor of philosophy degree and have for the most part become over-educated and over-paid technicians. Granted, there are a large number of excellent practitioners in pharmacy, but they are in the minority. How much longer will our schools continue to graduate technically qualified individuals who will soon become an LETTERS Heparin and aminoglycosides instability TO THE EDITOR: It has been recognized for some time that there is a physical incompatibility between undiluted heparin and gentamicin such that when the two are mixed a cloudy precipitate is formed. This redissolves when the mixture is diluted. There appears to be no resultant diminution in antibiotic activity of the gentamicin, although loss of heparin effect has been demonstrated.t' I observed the formation of a precipitate while giving tobramycin via a heparinized intravenous cannula and proceeded to test the behavior of undiluted heparin mixed with netilmicin and with amikacin. A similar white precipitate developed in each case. The data sheet for heparin states that precipitation or loss of potency can result from mixture with other drugs. Incompatibility of heparin with aminoglycosides is specifically mentioned on data sheets for gentamicin and kanamycin, but not for tobramycin, netilmicin, or amikacin.
It is common practice to administer aminoglycosides via heparinized intravenous cannulas. Ideally a weak solution of heparin (e.g., 10 V/ml) should be used to maintain cannula patency; but where "locking" with undiluted heparin is necessary, the heparin should be withdrawn into a separate syringe before injecting an aminoglycoside and the cannula should be flushed with NaCI 0.9010 before a fresh heparin lock is applied. STEPHEN M.W. HUTCHISON, M.B., M.R.C.P.
Registrar in Medicine Medical Renal Unit The Royal Infirmary of Edinburgh Lauriston Place Edinburgh EH3 9YW Scotland
albatross around the neck of our profession? ... Surely it is only a matter of time before government officials recognize that one does not need a five-year education to sell hose of the "panty" and "garden" varieties. This is a luxury our health-care system cannot afford and which soon may be exposed ....
Are basic scientists fiddling? Isn't it time to yield the reins governing professional practice to the clinical faculty?
Imipramine treatment failures: defective generic products or inadequate doses? TO THE EDITOR: Imipramine was introduced in the V.S. as an antidepressant drug in 1958 and its popularity spread, establishing it as the prototype agent in its class. Geigy Pharmaceuticals held the exclusive patent on imipramine, marketing it as Tofranil. Shortly following patent expiration, other companies began marketing generic forms of the drug.
Concern has repeatedly been expressed about the bioequivalence of generic psychotropic drugs I and anecdotal reports have surfaced raising doubts about the quality of generic antidepressants. Evidence for these failures has often been weak retrospective observations or single case reports, yet this information has drawn great attention.i-' In 1977 the Food and Drug Administration (FDA) stated that several brands of imipramine tablets, including Geigy's, were subject to bioequivalence problems when it was found that the coating of the 25 mg tablets hardened on aging, resulting in decreased dissolution."
Many physicians still have great concern when generic imipramine is dispensed to their patients. We recently encountered three patients who had subtherapeutic plasma imipramine concentrations after receiving generic imipramine and took steps to evaluate this problem.
These three patients were receivingimipramine 100mg/d, 150mg/d, and 200 mg/d, which produced total steady-state imipramine concentrations of 50 ng/ml, 22 ng/ml, and 49 ng/ml, respectively.
A cluster of three patients with subtherapeutic concentrations of imipramine raised suspicion that an ineffective product was being dispensed from the hospital pharmacy. Both psychiatrists (D.T. and A.H.) had experienced similar treatment failures in private practice when generic imipramine was substituted for Tofrani!. A visit to the hospital pharmacy revealed that, in fact, a generic imipramine (Bolar brand) had been used in the hospital for over a year. At this point evidence was mounting that the generic product was the culprit; however, it was still possible that the problem was laboratory error, lack of patient compliance, or that the doses prescribed were inadequate to produce therapeutic imipramine concentrations. To evaluate these possibilities several actions were planned.
An assessment of laboratory accuracy was made by obtaining a repeat plasma sample on case 2 at the same daily dose of imipramine.
